O'Day, Steven J <br/><br/>
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Mar 2013 
 - 1211-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2012.44.5585  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Disease-Free Survival<br/>Double-Blind Method<br/>Humans<br/>Hydrazines--administration & dosage<br/>L-Lactate Dehydrogenase--blood<br/>Melanoma--drug therapy<br/>Paclitaxel--administration & dosage<br/>Skin Neoplasms--drug therapy<br/>Treatment Outcome